The problems at the plant run by contract manufacturer Emergent BioSolutions first emerged a few weeks ago, after an FDA inspection uncovered a string of violations including that the building was “not maintained in a clean and sanitary condition.”
While the main issue was the discovery of AstraZeneca vaccine material in J&J batches, the inspectors also found peeling paint and damaged floors and walls that would prevent adequate cleaning, and waste materials that weren’t properly decontaminated before being shipped to other areas of the facility.
